Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CMAB807 vs Prolia in Postmenopausal Osteoporosis
NCT04591275Phase 3Completed
- Sponsor
- Shanghai Biomabs Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Nov 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of CMAB807 in postmenopausal osteoporosis, sponsored by Shanghai Biomabs Pharmaceuticals. Started Mar 2021; status: completed.
02
Drugs
CMAB807
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT04591275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04591275.